vTv Therapeutics Inc. 8-K

What Happened

• vTv Therapeutics, Inc. (VTVT) filed a Form 8-K on February 26, 2026 (Item 7.01) to disclose that it posted an updated investor slide presentation dated February 2026 on its website. The presentation is attached to the report as Exhibit 99.1 and may be used by company representatives in meetings with investors, analysts and other parties. The report was signed by Paul J. Sekhri, President and CEO.

Key Details

• Filing date: February 26, 2026 (Form 8-K, Item 7.01 — Regulation FD Disclosure).
• Exhibit: Updated investor presentation dated February 2026 attached as Exhibit 99.1.
• Use: Company reps will use the slides in investor/analyst meetings; the presentation may be amended or updated and further disclosed via future filings.
• Not included: This 8-K does not report earnings, revenue, executive changes, mergers, or financial statements beyond the exhibit attachment.

Why It Matters

• Posting an updated investor presentation under Regulation FD is how the company broadly shares corporate updates and investor-facing information. Retail investors should review the slides for any updates on strategy, clinical programs, timelines or financial outlook that could affect the company’s outlook. Because the presentation may be updated, check vTv’s investor website and subsequent SEC filings for the latest material information.